Randomized trial shows improved overall survival with ribociclib and fulvestrant in advanced breast cancer, indicating potential treatment benefits.
Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.).
No takes yet. Share an insight, caveat, or question.
Slamon et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: